academic article

• SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  72:2132-2140. 2021